Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) was the target of a significant increase in short interest in September. As of September 15th, there was short interest totaling 1,297,436 shares, an increase of 3,691.1% from the August 31st total of 34,223 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily volume of 588,083 shares, the days-to-cover ratio is presently 2.2 days.
Shionogi & Co., Ltd. Unsponsored ADR Price Performance
Shares of SGIOY stock traded down $0.14 during trading hours on Thursday, reaching $9.20. The company’s stock had a trading volume of 74,200 shares, compared to its average volume of 141,757. Shionogi & Co., Ltd. Unsponsored ADR has a fifty-two week low of $7.65 and a fifty-two week high of $12.00. The firm’s 50 day simple moving average is $9.07 and its 200-day simple moving average is $9.47. The company has a quick ratio of 1.00, a current ratio of 1.14 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $15.66 billion, a price-to-earnings ratio of 9.20, a PEG ratio of 3.37 and a beta of 0.08.
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 16.13% and a net margin of 46.67%.The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $970.69 million. Sell-side analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 earnings per share for the current year.
Analyst Upgrades and Downgrades
View Our Latest Analysis on SGIOY
Shionogi & Co., Ltd. Unsponsored ADR Company Profile
Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, the company has built its business around drug discovery and has a particular focus on infectious diseases, including antiviral and antibacterial treatments.
Shionogi’s products include Xofluza (baloxavir marboxil), an oral treatment for influenza, and Fetcroja (cefiderocol), an antibiotic used for certain difficult-to-treat bacterial infections.
Recommended Stories
- Five stocks we like better than Shionogi & Co., Ltd. Unsponsored ADR
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
